SYRE
Spyre Therapeutics Inc.
92.70$
-0.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | – | – | 100.0% | 100.0% | 100.0% | 100.0% | – | |
| – | 1.5% | – | – | – | – | – | 10.7% | 84.3% | 108.8% | 108.8% | – | |
| – | 98.5% | 100.0% | 100.0% | 100.0% | – | – | 100.0% | 100.0% | -8.8% | 100.0% | – | |
| – | 188.2% | 392.0% | 438.3% | 944.4% | – | – | 304.5% | 2,515.2% | 10,102.0% | 18,373.6% | – | |
| – | 97.7% | – | – | – | – | – | 145.8% | 1,225.0% | 4,508.6% | 5,166.6% | – | |
| – | 285.9% | 573.3% | 631.7% | 1,269.3% | – | – | 450.3% | 3,740.2% | 27,448.0% | 23,540.2% | – | |
| – | -185.9% | -473.3% | -531.7% | -1,169.3% | – | – | -350.3% | -3,640.2% | -27,348.0% | -23,540.2% | – | |
| – | -185.6% | -468.8% | -523.3% | -1,140.6% | – | – | -350.4% | -3,604.6% | -38,241.1% | -23,472.6% | – | |
| – | – | – | – | – | – | – | 0.8% | -5.8% | -2.9% | 5.8% | – | |
| – | -185.6% | -468.8% | -523.3% | -1,140.6% | – | – | -351.1% | -3,598.8% | -38,238.1% | -23,478.3% | – | |
| – | -184.5% | -470.5% | -526.9% | -1,161.8% | – | – | -342.0% | -3,520.3% | -27,348.0% | -23,472.6% | – |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.